MACROGENICS, INC. (NASDAQ:MGNX) Files An 8-K Other Events
ITEM 8.01.
| Other Events. |
On April 26, 2017, MacroGenics, Inc. (the Company) entered into a
Subscription Agreement (the Subscription Agreement) with an
investor not affiliated with the Company providing for the
issuance and sale by the Company of 1,100,000 shares of the
Companys common stock, par value $0.01 per share (the Shares), in
a registered direct offering (the Offering). The Shares were
offered at a price of $21.50 per Share. The closing of the
Offering is expected to occur on May 2, 2017.
The Company will receive gross proceeds from the Offering of
$23.65 million and the net proceeds are $23.6 million, after
deducting offering expenses. The Company intends to use the net
proceeds from the Offering to fund the continued advancement of
programs in its pipeline and other general corporate purposes,
including working capital.
The Shares were offered by the Company to a shelf registration
statement on Form S-3 (File No. 333-214385), filed with the
Securities and Exchange Commission (the SEC) on November 2, 2016.
The Shares may be offered only by means of a prospectus,
including a prospectus supplement, forming a part of the
effective registration statement.
This Current Report does not constitute an offer to sell the
Shares or a solicitation of an offer to buy these Shares, nor
shall there be any sale of these Shares in any state or
jurisdiction in which such an offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
This Current Report contains forward-looking statements that
involve risks and uncertainties, such as statements related to
the anticipated closing of the Offering and the amount and use of
net proceeds expected from the Offering. The risks and
uncertainties involved include the Companys ability to satisfy
certain conditions to closing on a timely basis or at all, as
well as other risks detailed from time to time in the Companys
SEC filings.
| ITEM 9.01. | Financial Statements and Exhibits. |
| Exhibit No. | Description | |
|
1.1 5.1 |
Form of Subscription Agreement dated April 26, 2017, Opinion of Covington Burling LLP. |
|
| 23.1 | Consent of Covington Burling LLP (included in Exhibit 5.1). |
About MACROGENICS, INC. (NASDAQ:MGNX)
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment. It develops therapeutic product candidates using its antibody-based technology platforms and in partnership with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily against various cancers. Its product candidates include margetuximab, enoblituzumab, MGD006, MGD007, MGD011, MGD009, MGD013, MGD010, teplizumab and MGD014. Its clinical product candidate, margetuximab, is a monoclonal antibody directed against human epidermal growth factor receptor 2, (HER2), including certain types of breast and gastroesophageal cancers. MACROGENICS, INC. (NASDAQ:MGNX) Recent Trading Information
MACROGENICS, INC. (NASDAQ:MGNX) closed its last trading session up +0.18 at 21.68 with 138,224 shares trading hands.